Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Clovis Oncology Inc (NQ: CLVS)
3.120 USD  -0.150 (-4.59%)
Official Closing Price  /  Updated: 5:08 PM EDT, Oct 14, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,080,800
Open 3.300
Bid (Size) 3.100 (10)
Ask (Size) 3.240 (4)
Prev. Close 3.270
Today's Range 3.110 - 3.360
52wk Range 3.110 - 32.05
Shares Outstanding 52,548,995
Dividend Yield N/A
Performance
YTD
-83.91%
-83.91%
1 Month
-44.78%
-44.78%
3 Month
-75.93%
-75.93%
6 Month
-84.82%
-84.82%
1 Year
-88.79%
-88.79%
Top News
More News
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to... Read More
from Business Wire News Releases
3 Beaten-Up Biotechs -- Are They Buys?
Is it finally time to add these three fallen biotech stocks to your portfolio? Read More
category Market News , CLVS , RGNX , and 1 more.
from Motley Fool
More News
Read More
Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the E
from Business Wire News Releases
3 Cancer Treatment Stocks to Buy Right Now
category PBYI , AGEN , Market News , and 1 more.
from Motley Fool
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
category Price Target , Benzinga , AZN , and 14 more.
from Benzinga
AstraZeneca strengthens Lynparza push with prostate cancer data
category companyNews
from Reuters: Company News
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
category ADVM , MDCO , ARPO , and 65 more.
from Benzinga
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
category URGN , TRVI , INMB , and 63 more.
from Benzinga
Stocks That Hit 52-Week Lows On Wednesday
category SOUHY , BYDDY , TTPH , and 196 more.
from Benzinga
Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding?
category GSK , EXEL , CELG , and 21 more.
from Motley Fool
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
category Biotech , STSA , TTPH , and 68 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.